To establish the impact of currently approved gene therapy treatments, which are designed to increase SMN levels in SMA patients, on a peripheral tissue such as the heart, we examined the extent to which AAV9-mediated SMN1 treatment restored expression levels of lamin A/C and desmin towards control mice. Here, SMN2 is linked to proximal spinal muscular atrophy.